TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33719606

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections after ultrasound-guided percutaneous lavage (UGPL)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Calcium extraction during UGPL
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Communication created between the calcification and the subacromial bursa during UGPL
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lower DASH score at 3 months
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lower DASH score at 6 months
Number of subjects: 132
Study: 32035854

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Guide (SG) training
Number of subjects: 20
Study: 36501840

Group type: EXPERIMENTAL
Intervention: High cuff pressure (HP: 80% of the arterial occlusion pressure)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low cuff pressure (LP: 40% of the arterial occlusion pressure)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High cuff pressure (HP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low cuff pressure (LP)
Number of subjects: 12
Study: 34015952

Group type: EXPERIMENTAL
Intervention: Supported Employment Demonstration (SED) intervention
Number of subjects: 2960
Study: 32116250

Group type: EXPERIMENTAL
Intervention: DHA supplementation for 18 months
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 33595760

Group type: EXPERIMENTAL
Intervention: Our proposed framework for automatic myocardial segmentation
Number of subjects: 100

Group type: COMPARATOR
Intervention: U-net (traditional segmentation model)
Number of subjects: 100

Group type: COMPARATOR
Intervention: U-net + forward (model considering only forward temporal information)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Visual grading study performance of our framework
Number of subjects: 100
Study: 36425395

Group type: EXPERIMENTAL
Intervention: Specific strength training combined with a standard care exercise program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard care exercise program without targeted muscle strengthening
Number of subjects: 41
Study: 32415529

Group type: EXPERIMENTAL
Intervention: Self-efficacy, social support, and perceived access to exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy and perceived access to exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certain types of social support
Number of subjects: 0
Study: 36043887

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1181
Study: 33370477

Group type: EXPERIMENTAL
Intervention: Third-party bone marrow–derived MSC infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 20
Study: 32344650

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (10,000 UI/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 35393305

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (daily time-restricted eating; consuming food for not more than 8 hours/day, fasting for at least 16 hours/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group without a particular diet
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Number of subjects: 48
Study: 34489128

Group type: EXPERIMENTAL
Intervention: V114 (15-valent PCV) followed by PPSV23
Number of subjects: 652

Group type: COMPARATOR
Intervention: PCV13 followed by PPSV23
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: V114 followed by PPSV23
Number of subjects: 652
Study: 36277980

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medications
Number of subjects: 90
Study: 34021264

Group type: EXPERIMENTAL
Intervention: Weight management intervention (weekly weight management group combining commercial weight loss programme with clinical advice from midwives)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Usual care and leaflets on diet and physical activity in pregnancy (Control group)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Weight management intervention
Number of subjects: 598
Study: 32349528

Group type: EXPERIMENTAL
Intervention: Kinesio Taping intervention once a week for four weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Compression stockings for four weeks
Number of subjects: 62
Study: 35312012

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 539
Study: 33107056

Group type: EXPERIMENTAL
Intervention: mHealth apps targeting heart failure patients
Number of subjects: 10
Study: 36191268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2944
Study: 33987929

Group type: EXPERIMENTAL
Intervention: Bipolar coagulator used before suturing to control bleeding
Number of subjects: 50

Group type: COMPARATOR
Intervention: No bipolar coagulator used
Number of subjects: 50
Study: 35259534

Group type: EXPERIMENTAL
Intervention: As-needed use of SABAs plus ICS (beclomethasone dipropionate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: As-needed use of SABAs alone (albuterol)
Number of subjects: 0
Study: 33799795

Group type: EXPERIMENTAL
Intervention: Group 1 (overweight/obese)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group 0 (normal weight)
Number of subjects: 30
Study: 33092478

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 3279
Study: 36397049

Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation (ARP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Natural healing
Number of subjects: 70
Study: 33875532

Group type: EXPERIMENTAL
Intervention: 15-minute yoga intervention (gentle yoga movements, breathing, and meditation)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (usual pre-exam routines)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 15-minute yoga intervention
Number of subjects: 32
Study: 34053229

Group type: EXPERIMENTAL
Intervention: Single-point cane for one month
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 50
Study: 35461201

Group type: EXPERIMENTAL
Intervention: N+‐ANN model for predicting postoperative lymph node metastasis in the training group
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: N+‐ANN model for predicting postoperative lymph node metastasis in the validation group
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: N+‐ANN model for predicting pN staging
Number of subjects: 1231

Group type: COMPARATOR
Intervention: cN staging
Number of subjects: 1231
Study: 32538010

Group type: EXPERIMENTAL
Intervention: Acupuncture at lower-he acupoints and front-mu acupoints combined with Tongxieyaofang (TXYF), oral administration of TXYF three times a day, routine acupuncture once a day for four weeks.
Number of subjects: 123

Group type: COMPARATOR
Intervention: TXYF, oral administration of TXYF three times a day for four weeks.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Pinaverium bromide, 50 mg, oral administration three times a day for four weeks.
Number of subjects: 123
Study: 34741530

Group type: EXPERIMENTAL
Intervention: Pazopanib with FLO (5-fluorouracil, oxaliplatin)
Number of subjects: 78

Group type: COMPARATOR
Intervention: FLO alone (control)
Number of subjects: 78
Study: 33861704

Group type: EXPERIMENTAL
Intervention: Five-trial training
Number of subjects: 16

Group type: COMPARATOR
Intervention: One-trial training
Number of subjects: 16
Study: 32654400

Group type: EXPERIMENTAL
Intervention: Standard single pass (SP) emission with 755 alexandrite laser
Number of subjects: 108

Group type: COMPARATOR
Intervention: Multipass emission (Moveo handpiece) with 755 alexandrite laser
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 108
Study: 35119183

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study: 34984068

Group type: EXPERIMENTAL
Intervention: Two-step Resilience-Oriented Intervention (TROI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 70
Study: 34057133

Group type: EXPERIMENTAL
Intervention: Instrument‐assisted manual (IM) technique
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional static stretching (SS) technique
Number of subjects: 39

Group type: COMPARATOR
Intervention: Hold-relax (HR) manual technique
Number of subjects: 39
Study: 34664845

Group type: EXPERIMENTAL
Intervention: Auto-demand oxygen delivery system (auto-DODS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional demand oxygen delivery system (conventional DODS)
Number of subjects: 8
Study: 32467558

Group type: EXPERIMENTAL
Intervention: Ureteral catheter use during arteriovenous fistula
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no ureteral catheter)
Number of subjects: 50
Study: 36255564

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 106

Group type: COMPARATOR
Intervention: endoscopic + β‐blocker
Number of subjects: 106
Study: 33872051

Group type: EXPERIMENTAL
Intervention: Water vapor therapy (Rezūm™)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Crossover group (initially control)
Number of subjects: 197
Study: 35978446

Group type: EXPERIMENTAL
Intervention: Fluoxetine (Prozac) for 9 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calcium for 9 months
Number of subjects: 100
Study: 33394328

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: MAD
Number of subjects: 79
Study: 36087104

Group type: EXPERIMENTAL
Intervention: FODMAPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gluten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32965653

Group type: EXPERIMENTAL
Intervention: Regular follow-up and supportive interventions
Number of subjects: 38

Group type: COMPARATOR
Intervention: Children with idiopathic nephrotic syndrome
Number of subjects: 38
Study: 32267727

Group type: EXPERIMENTAL
Intervention: Moderate‐ to high‐intensity physical activity (PA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control day without PA
Number of subjects: 31
Study: 33351458

Group type: EXPERIMENTAL
Intervention: ERAS (Enhanced Recovery After Surgery)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 64
Study: 34076375

Group type: EXPERIMENTAL
Intervention: subgingival application of injectable platelet-rich fibrin (i-PRF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 15
Study: 34732271

Group type: EXPERIMENTAL
Intervention: Educative article featuring a person mastering a suicidal crisis
Number of subjects: 172

Group type: COMPARATOR
Intervention: Unrelated article (Control)
Number of subjects: 172
Study: 32936598

Group type: EXPERIMENTAL
Intervention: Hourly cycling sprints (4 s × 5 per hour × 8 h = 160 s·d SPRINTS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 8-h period of sitting (SIT)
Number of subjects: 8
Study: 34008525

Group type: EXPERIMENTAL
Intervention: Phacoemulsification‐goniosynechialysis (phaco‐GSL)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Phacotrabeculectomy
Number of subjects: 79
Study: 34180118

Group type: EXPERIMENTAL
Intervention: High sodium concentration (HNa, 143 mEq/L)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low sodium concentration (LNa, 138 mEq/L)
Number of subjects: 19
Study: 34260424

Group type: EXPERIMENTAL
Intervention: 2-hour repositioning interval using an air mattress
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 2-hour repositioning interval using a foam mattress
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 3-hour repositioning interval using a foam mattress
Number of subjects: 251
Study: 35788995

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32020028

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 50
Study: 35920763

Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 32854477

Group type: EXPERIMENTAL
Intervention: PD-1 and PD-L1 high expression in EOC tissues
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PD-1 high expression in serous carcinoma
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PD-L1 high expression in serous carcinoma
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PD-1 and PD-L1 high expression in early vs late stage EOC
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PD-1 and PD-L1 expression in high-grade vs low-grade EOC
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Survival analysis based on PD-1 and PD-L1 expression
Number of subjects: 180
Study: 36455284

Group type: EXPERIMENTAL
Intervention: Reduced injection technique (5 injection sites)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard injection technique (20 injection sites)
Number of subjects: 77
Study: 34455912

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 91
Study: 32321288

Group type: EXPERIMENTAL
Intervention: Low frequency stimulation of the sphenopalatine ganglion for 30 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation for 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low frequency stimulation
Number of subjects: 12
Study: 34995276

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 800

Group type: COMPARATOR
Intervention: Angiogram-guided PCI
Number of subjects: 800
Study: 33230924

Group type: EXPERIMENTAL
Intervention: Broad pre-eclampsia definition (proteinuria or one/more maternal symptoms, signs or abnormal laboratory tests)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Restrictive pre-eclampsia definition (new proteinuria)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Broad pre-eclampsia definition with addition of fetoplacental manifestations (stillbirth or birthweight <10th centile)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Main CHIPS trial outcomes
Number of subjects: 987
Study: 32822637

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation with a multiple independent constant current‐controlled device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 35361008

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study: 33314880

Group type: EXPERIMENTAL
Intervention: Low-intensity with blood flow restriction (LI-BFR; N=10; trained at 30-40% of VO2 reserve with BFR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-exercising control group (N=10)
Number of subjects: 39
Study: 32865374

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg daily
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 35077557

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 221
Study: 33744591

Group type: EXPERIMENTAL
Intervention: Matcha (2 g daily for 2 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 32614625

Group type: EXPERIMENTAL
Intervention: Respimat
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: pMDI
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diskhaler
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diskus
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Aerolizer
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Handihaler
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Turbohaler
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Breezhaler
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ellipta
Number of subjects: 180
Study: 35896167

Group type: EXPERIMENTAL
Intervention: Covexir® (F. foetida oleo-gum)
Number of subjects: 0
Study: 33359791

Group type: EXPERIMENTAL
Intervention: mAb AR9.6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mAb AR9.6 alone or in combination with gemcitabine
Number of subjects: 0
Study: 34297496

Group type: EXPERIMENTAL
Intervention: 30 mg abelacimab
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 75 mg abelacimab
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 150 mg abelacimab
Number of subjects: 412

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg)
Number of subjects: 412
Study: 33227220

Group type: EXPERIMENTAL
Intervention: PBMT (60 J; 1152 mW; 52 sec; and 166.75 cm2) applied on biceps brachii
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 35000898

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) treatment
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo (P) treatment
Number of subjects: 303
Study: 33984185

Group type: EXPERIMENTAL
Intervention: Ceramide-dominant moisturizing cream and cleanser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34088244

Group type: EXPERIMENTAL
Intervention: Digital storytelling video
Number of subjects: 247

Group type: COMPARATOR
Intervention: Brochure
Number of subjects: 247
Study: 33629973

Group type: EXPERIMENTAL
Intervention: Intermittent palm cooling during exercise (PCex)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intermittent palm cooling during and post-exercise (PCex&post)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No palm cooling (NoPC)
Number of subjects: 34
Study: 35642832

Group type: EXPERIMENTAL
Intervention: Fibrinogen administration
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 32242806

Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 35150788

Group type: EXPERIMENTAL
Intervention: HF1 (39 Gy in 13 fractions)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: HF2 (45 Gy in 15 fractions)
Number of subjects: 253

Group type: COMPARATOR
Intervention: CF (54 Gy in 30 fractions)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: HF1
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: HF2
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Younger patients (2-5 years)
Number of subjects: 253
Study: 32164767

Group type: EXPERIMENTAL
Intervention: Serelaxin (80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 34355605

Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill rehabilitation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard rehabilitation (control)
Number of subjects: 73
Study: 34130035

Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia (33–35 °C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normothermia (37 °C)
Number of subjects: 40
Study: 34866567

Group type: EXPERIMENTAL
Intervention: Adapted CBT (BIACA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard-of-practice CBT (CC)
Number of subjects: 202
Study: 33222296

Group type: EXPERIMENTAL
Intervention: 4-implants (4-I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 6-implants (6-I)
Number of subjects: 56
Study: 36354206

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (1.0-1.5 MAC)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia (2.0-3.0 mg/kg/h)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 289

Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia
Number of subjects: 289
Study: 33877728

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg/day for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 32513881

Group type: EXPERIMENTAL
Intervention: For Our Children's Sake (FOCS) intervention, group format over 10 weeks
Number of subjects: 76
Study: 35353909

Group type: EXPERIMENTAL
Intervention: Worry induction
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Worry reduction
Number of subjects: 90

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trait worry
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Participants with internalizing disorders
Number of subjects: 90
Study: 34559837

Group type: EXPERIMENTAL
Intervention: MoveStrong program (balance and functional strength training with protein intake focus)
Number of subjects: 44
Study: 32333847

Group type: COMPARATOR
Intervention: AVA (Anthrax Vaccine Adsorbed)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: AVA plus raxibacumab
Number of subjects: 573

Group type: COMPARATOR
Intervention: Comparison of AVA and AVA plus raxibacumab
Number of subjects: 573

Group type: COMPARATOR
Intervention: Safety population
Number of subjects: 573
Study: 35256150

Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose 1000 mg and darbepoetin 200 μg subcutaneously
Number of subjects: 156

Group type: COMPARATOR
Intervention: Oral ferrous sulphate 600 mg daily
Number of subjects: 156
Study: 34187756

Group type: EXPERIMENTAL
Intervention: High-frequency (HF) transcutaneous auricular vagus nerve stimulation at 25Hz
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low-frequency (LF) transcutaneous auricular vagus nerve stimulation at 1Hz
Number of subjects: 57
Study: 35296793

Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN) for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group received intensive dietary counselling for 3 months
Number of subjects: 38
Study: 35103070

Group type: EXPERIMENTAL
Intervention: Hypertonic saline aerosol inhalation (3% saline)
Number of subjects: 0
Study: 34232160

Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability (BPv)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CVD events from long-term posttrial follow-up (ACCORDION)
Number of subjects: 0
Study: 35553187

Group type: EXPERIMENTAL
Intervention: ebselen (10 mg/kg i.p.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 11